Lead optimization of spiropyrazolopyridones

A new and potent class of dengue virus inhibitors

Bin Zou, Wai Ling Chan, Mei Ding, Seh Yong Leong, Shahul Nilar, Peck Gee Seah, Wei Liu, Ratna Karuna, Francesca Blasco, Andy Yip, Alex Chao, Agatha Susila, Hongping Dong, Qing Yin Wang, Hao Ying Xu, Katherine Chan, Kah Fei Wan, Feng Gu, Thierry T. Diagana, Trixie Wagner & 3 others Ina Dix, Pei-Yong Shi, Paul W. Smith

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Spiropyrazolopyridone 1 was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen. As a general trend within this chemical class, chiral resolution of the racemate revealed that R enantiomer was significantly more potent than the S. Cell-based lead optimization of the spiropyrazolopyridones focusing on improving the physicochemical properties is described. As a result, an optimal compound 14a, with balanced in vitro potency and pharmacokinetic profile, achieved about 1.9 log viremia reduction at 3 × 50 mg/kg (bid) or 3 × 100 mg/kg (QD) oral doses in the dengue in vivo mouse efficacy model.

Original languageEnglish (US)
Pages (from-to)344-348
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume6
Issue number3
DOIs
StatePublished - Mar 12 2015
Externally publishedYes

Fingerprint

Dengue Virus
Viruses
Pharmacokinetics
Enantiomers
Dengue
Viremia
Throughput
Lead
Serogroup
In Vitro Techniques

Keywords

  • Dengue virus (DENV)
  • lead optimization
  • spiropyrazolopyridones
  • structure-activity relationship

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Zou, B., Chan, W. L., Ding, M., Leong, S. Y., Nilar, S., Seah, P. G., ... Smith, P. W. (2015). Lead optimization of spiropyrazolopyridones: A new and potent class of dengue virus inhibitors. ACS Medicinal Chemistry Letters, 6(3), 344-348. https://doi.org/10.1021/ml500521r

Lead optimization of spiropyrazolopyridones : A new and potent class of dengue virus inhibitors. / Zou, Bin; Chan, Wai Ling; Ding, Mei; Leong, Seh Yong; Nilar, Shahul; Seah, Peck Gee; Liu, Wei; Karuna, Ratna; Blasco, Francesca; Yip, Andy; Chao, Alex; Susila, Agatha; Dong, Hongping; Wang, Qing Yin; Xu, Hao Ying; Chan, Katherine; Wan, Kah Fei; Gu, Feng; Diagana, Thierry T.; Wagner, Trixie; Dix, Ina; Shi, Pei-Yong; Smith, Paul W.

In: ACS Medicinal Chemistry Letters, Vol. 6, No. 3, 12.03.2015, p. 344-348.

Research output: Contribution to journalArticle

Zou, B, Chan, WL, Ding, M, Leong, SY, Nilar, S, Seah, PG, Liu, W, Karuna, R, Blasco, F, Yip, A, Chao, A, Susila, A, Dong, H, Wang, QY, Xu, HY, Chan, K, Wan, KF, Gu, F, Diagana, TT, Wagner, T, Dix, I, Shi, P-Y & Smith, PW 2015, 'Lead optimization of spiropyrazolopyridones: A new and potent class of dengue virus inhibitors', ACS Medicinal Chemistry Letters, vol. 6, no. 3, pp. 344-348. https://doi.org/10.1021/ml500521r
Zou, Bin ; Chan, Wai Ling ; Ding, Mei ; Leong, Seh Yong ; Nilar, Shahul ; Seah, Peck Gee ; Liu, Wei ; Karuna, Ratna ; Blasco, Francesca ; Yip, Andy ; Chao, Alex ; Susila, Agatha ; Dong, Hongping ; Wang, Qing Yin ; Xu, Hao Ying ; Chan, Katherine ; Wan, Kah Fei ; Gu, Feng ; Diagana, Thierry T. ; Wagner, Trixie ; Dix, Ina ; Shi, Pei-Yong ; Smith, Paul W. / Lead optimization of spiropyrazolopyridones : A new and potent class of dengue virus inhibitors. In: ACS Medicinal Chemistry Letters. 2015 ; Vol. 6, No. 3. pp. 344-348.
@article{37cd55aadbaf498fb454b98549ace7a6,
title = "Lead optimization of spiropyrazolopyridones: A new and potent class of dengue virus inhibitors",
abstract = "Spiropyrazolopyridone 1 was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen. As a general trend within this chemical class, chiral resolution of the racemate revealed that R enantiomer was significantly more potent than the S. Cell-based lead optimization of the spiropyrazolopyridones focusing on improving the physicochemical properties is described. As a result, an optimal compound 14a, with balanced in vitro potency and pharmacokinetic profile, achieved about 1.9 log viremia reduction at 3 × 50 mg/kg (bid) or 3 × 100 mg/kg (QD) oral doses in the dengue in vivo mouse efficacy model.",
keywords = "Dengue virus (DENV), lead optimization, spiropyrazolopyridones, structure-activity relationship",
author = "Bin Zou and Chan, {Wai Ling} and Mei Ding and Leong, {Seh Yong} and Shahul Nilar and Seah, {Peck Gee} and Wei Liu and Ratna Karuna and Francesca Blasco and Andy Yip and Alex Chao and Agatha Susila and Hongping Dong and Wang, {Qing Yin} and Xu, {Hao Ying} and Katherine Chan and Wan, {Kah Fei} and Feng Gu and Diagana, {Thierry T.} and Trixie Wagner and Ina Dix and Pei-Yong Shi and Smith, {Paul W.}",
year = "2015",
month = "3",
day = "12",
doi = "10.1021/ml500521r",
language = "English (US)",
volume = "6",
pages = "344--348",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Lead optimization of spiropyrazolopyridones

T2 - A new and potent class of dengue virus inhibitors

AU - Zou, Bin

AU - Chan, Wai Ling

AU - Ding, Mei

AU - Leong, Seh Yong

AU - Nilar, Shahul

AU - Seah, Peck Gee

AU - Liu, Wei

AU - Karuna, Ratna

AU - Blasco, Francesca

AU - Yip, Andy

AU - Chao, Alex

AU - Susila, Agatha

AU - Dong, Hongping

AU - Wang, Qing Yin

AU - Xu, Hao Ying

AU - Chan, Katherine

AU - Wan, Kah Fei

AU - Gu, Feng

AU - Diagana, Thierry T.

AU - Wagner, Trixie

AU - Dix, Ina

AU - Shi, Pei-Yong

AU - Smith, Paul W.

PY - 2015/3/12

Y1 - 2015/3/12

N2 - Spiropyrazolopyridone 1 was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen. As a general trend within this chemical class, chiral resolution of the racemate revealed that R enantiomer was significantly more potent than the S. Cell-based lead optimization of the spiropyrazolopyridones focusing on improving the physicochemical properties is described. As a result, an optimal compound 14a, with balanced in vitro potency and pharmacokinetic profile, achieved about 1.9 log viremia reduction at 3 × 50 mg/kg (bid) or 3 × 100 mg/kg (QD) oral doses in the dengue in vivo mouse efficacy model.

AB - Spiropyrazolopyridone 1 was identified, as a novel dengue virus (DENV) inhibitor, from a DENV serotype 2 (DENV-2) high-throughput phenotypic screen. As a general trend within this chemical class, chiral resolution of the racemate revealed that R enantiomer was significantly more potent than the S. Cell-based lead optimization of the spiropyrazolopyridones focusing on improving the physicochemical properties is described. As a result, an optimal compound 14a, with balanced in vitro potency and pharmacokinetic profile, achieved about 1.9 log viremia reduction at 3 × 50 mg/kg (bid) or 3 × 100 mg/kg (QD) oral doses in the dengue in vivo mouse efficacy model.

KW - Dengue virus (DENV)

KW - lead optimization

KW - spiropyrazolopyridones

KW - structure-activity relationship

UR - http://www.scopus.com/inward/record.url?scp=84924719200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924719200&partnerID=8YFLogxK

U2 - 10.1021/ml500521r

DO - 10.1021/ml500521r

M3 - Article

VL - 6

SP - 344

EP - 348

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 3

ER -